TuHURA Biosciences (HURA) vs Seer (SEER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Seer (SEER) has outperformed TuHURA Biosciences (HURA) over the past year, losing 6.0% versus a loss of 26.7%. Over five years, SEER leads with a -93.9% price change compared with -99.9% for HURA. Seer is the larger company by market cap ($112.4 million vs $112.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | SEER |
|---|---|---|
| Share price | $1.76 | $2.03 |
| Market cap | $112.16M | $112.41M |
| 1-day change | -3.83% | -0.49% |
| YTD return | +132.50% | +10.93% |
| 1-year return | -26.67% | -6.02% |
| 5-year return | -99.89% | -93.94% |
| EPS (TTM) | $-0.54 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $16.58M |
| Revenue growth (YoY) | — | +16.99% |
| Net income (latest FY) | $-30.05M | $-73.60M |
| Gross margin | — | 51.06% |
| Operating margin | — | -470.45% |
| Net margin | — | -443.96% |
| 52-week high | $3.43 | $2.41 |
| 52-week low | $0.41 | $1.55 |
| Distance from 52-week high | -48.69% | -15.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +356.82% | +97.04% |
| Average volume | 221.74K | 469.41K |
| Shares outstanding | 63.73M | 55.37M |
| Employees | 22 | 124 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEER has outperformed HURA by 20.6 percentage points over the past year.
- The two companies sit in different sectors: TuHURA Biosciences in Health Care and Seer in Industrials.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Seer
SEER stock →Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Industrials · Biotechnology: Laboratory Analytical Instruments · 124 employees
HURA vs SEER FAQ
Which is bigger, TuHURA Biosciences or Seer?
Seer (SEER) is larger, with a market capitalization of $112.41M compared with $112.16M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, HURA or SEER?
SEER returned -6.02% over the past 12 months, compared with -26.67% for HURA (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and Seer in the same industry?
No. TuHURA Biosciences is in the Health Care sector, while Seer is in Industrials.